Research programme: allogeneic chimeric antigen receptors macrophages - CARISMA Therapeutics/University of Minnesota
Alternative Names: Allogeneic CAR-Macrophages - Carisma Therapeutics; iPSC derived allogeneic chimeric antigen receptor macrophages - Carisma TherapeuticsLatest Information Update: 24 Jun 2021
At a glance
- Originator Carisma Therapeutics; University of Minnesota
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Macrophage replacements; Phagocyte stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer; Unspecified